Hot Investor Mandate 4: China-based Pharma Seeks Early Stage Investments in Drugs, Nutraceuticals and Digital Health

23 Feb

A publicly traded pharma corporation based in China is actively pursuing strategic partnerships with other pharmaceutical companies, natural product producers, universities, hospitals and researchers and developers. The firm considers a board range of strategies including investment, joint venture, acquisition, licensing, and development funding. The firm is looking for opportunities in North America and Europe.

The firm is looking for strategic partnerships in prescription drugs, nutraceuticals, and digital health. Other sectors of interest include healthcare services, children’s health education, and senior care. The firm is open to products at all development stages. Within biopharmaceuticals, the firm takes an opportunistic approach to small molecules, biologics, and other modalities. Within digital health, the firm is looking for products that are complimentary to its pipeline.

The firm is looking to build collaborative partnerships with experienced teams in key strategic sectors. The firm can provide US regulatory expertise, global operation, and distribution channels and clinical trial sites across China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: